FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W160400900> ?p ?o ?g. }

• W160400900 endingPage "498" @default.
• W160400900 startingPage "480" @default.
• W160400900 abstract "Purpose: To examine FOLFOX/bevacizumab/cetuximab in the first-line treatment of metastatic colorectal cancer (mCRC). Meth- ods: Design: Randomized phase II trial aimed at achieving a 60% objective response rate (ORR). Due to frequent cetuximab-related hypersensitivity reactions the trial was amended to a single-arm design. Eligibility: Previously untreated mCRC, measurable disease, Eastern Cooperative Oncology Group performance status (ECOG- PS) 0-1. Treatment: Modified FOLFOX6 (oxaliplatin 85 mg/m2 , leucovorin 350 mg, and 5-fluorouracil 400 mg/m2 bolus; 2.4 g/m 2 infusion, 46 h) day 1; bevacizumab 5 mg/kg on day 1; cetuximab 400 mg/m2 on day 1, then 250 mg/m 2 on days 1 and 8, every 14 days (1 cycle) until progressive disease (PD); restaging occurred every 4 cycles. Results: With emerging negative progression-free survival (PFS) data from a similarly designed trial, this trial closed early. Enroll- ment (N=31) was from August 2005-June 2008. Patient characteris- tics: Median age was 55 years (29-78); 58% were male; 71% were ECOG-PS 0. Ten cycles (median) were completed (range 2-62). The ORR was 55% (95% confidence interval (CI), 36-73%); 11 patients (35%) had stable disease; 1 patient (3%) had PD; 2 patients (6%) were unevaluable. Median PFS was 9 months (95% CI, 8.3-15.2 months); median overall survival was 25.7 months (95% CI, 15.4- 27.6 months). Grade 3/4 toxicities (>1 patient) included neutrope- nia (25%), rash (23%; grade 2 events, 45%), diarrhea (19%), fatigue (16%), pain (16%), anemia (13%), sensory neuropathy (13%), deep- vein thrombosis (10%), nausea (10%), pulmonary embolism (7%), anorexia (6%), and vomiting (6%). Conclusion: In this limited trial, it is unclear whether cetuximab contributed to FOLFOX/bevacizumab efficacy, although the response rate, PFS, and overall survival were high. The regimen was generally well-tolerated, with expected skin effects; thromboembolic rates should be assessed in larger analyses. Cetuximab's role in first-line mCRC treatment is likely best guided by K-RAS testing in future clinical trials." @default.
• W160400900 created "2016-06-24" @default.
• W160400900 creator A5018054038 @default.
• W160400900 creator A5028472820 @default.
• W160400900 creator A5028976895 @default.
• W160400900 creator A5050610940 @default.
• W160400900 creator A5053359739 @default.
• W160400900 creator A5057644746 @default.
• W160400900 creator A5065917441 @default.
• W160400900 creator A5072308451 @default.
• W160400900 creator A5076209303 @default.
• W160400900 creator A5079398298 @default.
• W160400900 creator A5086611845 @default.
• W160400900 date "2010-07-01" @default.
• W160400900 modified "2023-09-23" @default.
• W160400900 title "Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer." @default.
• W160400900 cites W1782669727 @default.
• W160400900 cites W1979300931 @default.
• W160400900 cites W2002226820 @default.
• W160400900 cites W2097121246 @default.
• W160400900 cites W2097644228 @default.
• W160400900 cites W2107666024 @default.
• W160400900 cites W2125447919 @default.
• W160400900 cites W2128176473 @default.
• W160400900 cites W2139119404 @default.
• W160400900 cites W2139248078 @default.
• W160400900 cites W2140035322 @default.
• W160400900 cites W2141632745 @default.
• W160400900 cites W2142374454 @default.
• W160400900 cites W2142564546 @default.
• W160400900 cites W2155311724 @default.
• W160400900 cites W2155977433 @default.
• W160400900 cites W2157769714 @default.
• W160400900 cites W2170655985 @default.
• W160400900 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20864916" @default.
• W160400900 hasPublicationYear "2010" @default.
• W160400900 type Work @default.
• W160400900 sameAs 160400900 @default.
• W160400900 citedByCount "2" @default.
• W160400900 countsByYear W1604009002015 @default.
• W160400900 crossrefType "journal-article" @default.
• W160400900 hasAuthorship W160400900A5018054038 @default.
• W160400900 hasAuthorship W160400900A5028472820 @default.
• W160400900 hasAuthorship W160400900A5028976895 @default.
• W160400900 hasAuthorship W160400900A5050610940 @default.
• W160400900 hasAuthorship W160400900A5053359739 @default.
• W160400900 hasAuthorship W160400900A5057644746 @default.
• W160400900 hasAuthorship W160400900A5065917441 @default.
• W160400900 hasAuthorship W160400900A5072308451 @default.
• W160400900 hasAuthorship W160400900A5076209303 @default.
• W160400900 hasAuthorship W160400900A5079398298 @default.
• W160400900 hasAuthorship W160400900A5086611845 @default.
• W160400900 hasConcept C121608353 @default.
• W160400900 hasConcept C126322002 @default.
• W160400900 hasConcept C141071460 @default.
• W160400900 hasConcept C143998085 @default.
• W160400900 hasConcept C2776694085 @default.
• W160400900 hasConcept C2777802072 @default.
• W160400900 hasConcept C2778260052 @default.
• W160400900 hasConcept C2778496288 @default.
• W160400900 hasConcept C2778570526 @default.
• W160400900 hasConcept C2778822529 @default.
• W160400900 hasConcept C2779998722 @default.
• W160400900 hasConcept C2780739268 @default.
• W160400900 hasConcept C2780962732 @default.
• W160400900 hasConcept C31760486 @default.
• W160400900 hasConcept C526805850 @default.
• W160400900 hasConcept C71924100 @default.
• W160400900 hasConcept C90924648 @default.
• W160400900 hasConceptScore W160400900C121608353 @default.
• W160400900 hasConceptScore W160400900C126322002 @default.
• W160400900 hasConceptScore W160400900C141071460 @default.
• W160400900 hasConceptScore W160400900C143998085 @default.
• W160400900 hasConceptScore W160400900C2776694085 @default.
• W160400900 hasConceptScore W160400900C2777802072 @default.
• W160400900 hasConceptScore W160400900C2778260052 @default.
• W160400900 hasConceptScore W160400900C2778496288 @default.
• W160400900 hasConceptScore W160400900C2778570526 @default.
• W160400900 hasConceptScore W160400900C2778822529 @default.
• W160400900 hasConceptScore W160400900C2779998722 @default.
• W160400900 hasConceptScore W160400900C2780739268 @default.
• W160400900 hasConceptScore W160400900C2780962732 @default.
• W160400900 hasConceptScore W160400900C31760486 @default.
• W160400900 hasConceptScore W160400900C526805850 @default.
• W160400900 hasConceptScore W160400900C71924100 @default.
• W160400900 hasConceptScore W160400900C90924648 @default.
• W160400900 hasIssue "7" @default.
• W160400900 hasLocation W1604009001 @default.
• W160400900 hasLocation W1604009002 @default.
• W160400900 hasOpenAccess W160400900 @default.
• W160400900 hasPrimaryLocation W1604009001 @default.
• W160400900 hasRelatedWork W1972813927 @default.
• W160400900 hasRelatedWork W2003387704 @default.
• W160400900 hasRelatedWork W2009643194 @default.
• W160400900 hasRelatedWork W2068577096 @default.
• W160400900 hasRelatedWork W2075342258 @default.
• W160400900 hasRelatedWork W2101112965 @default.
• W160400900 hasRelatedWork W2110746169 @default.

• next